Oncology and hematology: achieving fast price reimbursement approval and rapid market penetration
The emergence of technologies such as CAR T-cells and use of combinations or sequences of innovative agents presents unique challenges for your asset. We can provide the experience and insight needed to maximize your pricing and reimbursement opportunities.
More than half of our consulting work is in oncology, including some of the most innovative products coming to market.
Innovative and pragmatic solutions to get the best pricing and reimbursement outcomes for your oncology assets
We understand the trade-offs between providing early access to innovative therapies and payers’ calls for proven value and a strong evidence base.
Examples of the disease areas we have worked in include:
- solid tumors, such as breast, gastric, kidney, lung, and prostate cancer
- leukemia, lymphoma, and myeloma
- central nervous system tumors.
Accelerate market access and competitive advantage for your oncology asset
PRMA Consulting provide you with cutting-edge pricing and reimbursement solutions. Our creative recommendations, strategic insights, and in-depth research are clearly written and presented, delivered on time and on budget. Our depth of experience within oncology and access to a multidisciplinary network of global advisors means that we will come to your project with a specialist understanding of the issues involved.Request a call